Cargando…

2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017

BACKGROUND: Several studies have documented factors predictive of antimicrobial resistance (AMR) in invasive pneumococcal disease(IPD). However, the implementation of routine pediatric PCV programs, antimicrobial stewardship, and increasing immunocompromised in populating might be expected to change...

Descripción completa

Detalles Bibliográficos
Autores principales: Fear, Thomas, Green, Karen, Plevneshi, Agron, Li, Jeff, Rudnick, Wallis, Nayani, Sarah, McGeer, Allison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254773/
http://dx.doi.org/10.1093/ofid/ofy210.2054
_version_ 1783373802041769984
author Fear, Thomas
Green, Karen
Plevneshi, Agron
Li, Jeff
Rudnick, Wallis
Nayani, Sarah
McGeer, Allison
author_facet Fear, Thomas
Green, Karen
Plevneshi, Agron
Li, Jeff
Rudnick, Wallis
Nayani, Sarah
McGeer, Allison
author_sort Fear, Thomas
collection PubMed
description BACKGROUND: Several studies have documented factors predictive of antimicrobial resistance (AMR) in invasive pneumococcal disease(IPD). However, the implementation of routine pediatric PCV programs, antimicrobial stewardship, and increasing immunocompromised in populating might be expected to change such factors. We report on predictive factors for AMR in IPD from 2012 to 2017. METHODS: TIBDN performs population-based surveillance for IPD in Toronto/Peel (pop 4.5M). IPD cases are reported to a central office and one isolate/case is serotyped and has antimicrobial susceptibility testing performed by broth microdilution to CLSI standards. RESULTS: 2459 cases of IPD were identified from January 2012 to December 2017. Overall rates of resistance to penicillin, macrolides, fluoroquinolones, and TMP-SMX were relatively stable over the course were stable over the study. Risk factors for infection with resistant to penicillin at meningitis breakpoints as opposed to penicillin- susceptible pneumococci were current residence at nursing home (odds ratio [OR], 2.30; P < 0.001), immune compromised status (OR, 1.41; P = 0.012), HIV infection (OR 2.13, P = 0.016), history of receiving PPV23 vaccine (OR 1.38; P = 0.007). Infection with TMP-SMX-resistant pneumococci was associated with HIV infection (OR, 3.2; P = 0.001) and current residence in a nursing home (OR 2.4, P = 0.002). Infection with macrolide-resistant isolates was associated with any use of macrolide 3 months prior to infection (OR, 3.24; P < 0.001), or macrolide treatment failure of the current episode (OR, 6.64; P = 0.003). Infection with levofloxacin-resistant pneumococci was associated with current residence in a nursing home (OR, 13.7; P < .001), and fluorquinolone treatment failure of the current episode (OR 49.4, P = 0.0034). CONCLUSION: Previous same class antibiotic exposure remains a major predictive factor for macrolide resistance. History of treatment failure is a predictive factor for macrolide and fluoroquinolone failure. HIV infection and immune compromise are risk factors for IPD infection with penicillin resistant pneumococci. Hospital acquisition of infection is no longer a risk factor for fluoroquinolone resistance. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6254773
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62547732018-11-28 2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017 Fear, Thomas Green, Karen Plevneshi, Agron Li, Jeff Rudnick, Wallis Nayani, Sarah McGeer, Allison Open Forum Infect Dis Abstracts BACKGROUND: Several studies have documented factors predictive of antimicrobial resistance (AMR) in invasive pneumococcal disease(IPD). However, the implementation of routine pediatric PCV programs, antimicrobial stewardship, and increasing immunocompromised in populating might be expected to change such factors. We report on predictive factors for AMR in IPD from 2012 to 2017. METHODS: TIBDN performs population-based surveillance for IPD in Toronto/Peel (pop 4.5M). IPD cases are reported to a central office and one isolate/case is serotyped and has antimicrobial susceptibility testing performed by broth microdilution to CLSI standards. RESULTS: 2459 cases of IPD were identified from January 2012 to December 2017. Overall rates of resistance to penicillin, macrolides, fluoroquinolones, and TMP-SMX were relatively stable over the course were stable over the study. Risk factors for infection with resistant to penicillin at meningitis breakpoints as opposed to penicillin- susceptible pneumococci were current residence at nursing home (odds ratio [OR], 2.30; P < 0.001), immune compromised status (OR, 1.41; P = 0.012), HIV infection (OR 2.13, P = 0.016), history of receiving PPV23 vaccine (OR 1.38; P = 0.007). Infection with TMP-SMX-resistant pneumococci was associated with HIV infection (OR, 3.2; P = 0.001) and current residence in a nursing home (OR 2.4, P = 0.002). Infection with macrolide-resistant isolates was associated with any use of macrolide 3 months prior to infection (OR, 3.24; P < 0.001), or macrolide treatment failure of the current episode (OR, 6.64; P = 0.003). Infection with levofloxacin-resistant pneumococci was associated with current residence in a nursing home (OR, 13.7; P < .001), and fluorquinolone treatment failure of the current episode (OR 49.4, P = 0.0034). CONCLUSION: Previous same class antibiotic exposure remains a major predictive factor for macrolide resistance. History of treatment failure is a predictive factor for macrolide and fluoroquinolone failure. HIV infection and immune compromise are risk factors for IPD infection with penicillin resistant pneumococci. Hospital acquisition of infection is no longer a risk factor for fluoroquinolone resistance. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254773/ http://dx.doi.org/10.1093/ofid/ofy210.2054 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Fear, Thomas
Green, Karen
Plevneshi, Agron
Li, Jeff
Rudnick, Wallis
Nayani, Sarah
McGeer, Allison
2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017
title 2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017
title_full 2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017
title_fullStr 2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017
title_full_unstemmed 2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017
title_short 2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017
title_sort 2401. risk factors for antimicrobial resistance in invasive pneumococcal disease (ipd) in toronto, canada, 2012–2017
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254773/
http://dx.doi.org/10.1093/ofid/ofy210.2054
work_keys_str_mv AT fearthomas 2401riskfactorsforantimicrobialresistanceininvasivepneumococcaldiseaseipdintorontocanada20122017
AT greenkaren 2401riskfactorsforantimicrobialresistanceininvasivepneumococcaldiseaseipdintorontocanada20122017
AT plevneshiagron 2401riskfactorsforantimicrobialresistanceininvasivepneumococcaldiseaseipdintorontocanada20122017
AT lijeff 2401riskfactorsforantimicrobialresistanceininvasivepneumococcaldiseaseipdintorontocanada20122017
AT rudnickwallis 2401riskfactorsforantimicrobialresistanceininvasivepneumococcaldiseaseipdintorontocanada20122017
AT nayanisarah 2401riskfactorsforantimicrobialresistanceininvasivepneumococcaldiseaseipdintorontocanada20122017
AT mcgeerallison 2401riskfactorsforantimicrobialresistanceininvasivepneumococcaldiseaseipdintorontocanada20122017
AT 2401riskfactorsforantimicrobialresistanceininvasivepneumococcaldiseaseipdintorontocanada20122017